These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 17383050

  • 1. Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma.
    Opitz I, Sigrist B, Hillinger S, Lardinois D, Stahel R, Weder W, Hopkins-Donaldson S.
    Lung Cancer; 2007 Jun; 56(3):327-36. PubMed ID: 17383050
    [Abstract] [Full Text] [Related]

  • 2. Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment.
    Opitz I, Lardinois D, Arni S, Hillinger S, Vogt P, Odermatt B, Rousson V, Weder W.
    Eur J Cardiothorac Surg; 2007 May; 31(5):773-8. PubMed ID: 17350855
    [Abstract] [Full Text] [Related]

  • 3. Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.
    Brenes O, Arce F, Gätjens-Boniche O, Díaz C.
    Biomed Pharmacother; 2007 Jul; 61(6):347-55. PubMed ID: 17399942
    [Abstract] [Full Text] [Related]

  • 4. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
    Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL, Salgia R, Sugarbaker DJ, Bueno R.
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
    [Abstract] [Full Text] [Related]

  • 5. Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy.
    Varin E, Denoyelle C, Brotin E, Meryet-Figuière M, Giffard F, Abeilard E, Goux D, Gauduchon P, Icard P, Poulain L.
    Carcinogenesis; 2010 Jun; 31(6):984-93. PubMed ID: 20142415
    [Abstract] [Full Text] [Related]

  • 6. The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma.
    Nici L, Monfils B, Calabresi P.
    Clin Cancer Res; 2004 Nov 15; 10(22):7655-61. PubMed ID: 15569998
    [Abstract] [Full Text] [Related]

  • 7. Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma.
    Gordon GJ, Mani M, Mukhopadhyay L, Dong L, Yeap BY, Sugarbaker DJ, Bueno R.
    J Pathol; 2007 Mar 15; 211(4):439-46. PubMed ID: 17253597
    [Abstract] [Full Text] [Related]

  • 8. Phase-contrast microscopy studies of early cisplatin-induced morphological changes of malignant mesothelioma cells and the correspondence to induced apoptosis.
    Janson V, Behnam-Motlagh P, Henriksson R, Hörstedt P, Engström KG, Grankvist K.
    Exp Lung Res; 2008 Feb 15; 34(2):49-67. PubMed ID: 18266129
    [Abstract] [Full Text] [Related]

  • 9. Taurolidine and oxidative stress: a rationale for local treatment of mesothelioma.
    Aceto N, Bertino P, Barbone D, Tassi G, Manzo L, Porta C, Mutti L, Gaudino G.
    Eur Respir J; 2009 Dec 15; 34(6):1399-407. PubMed ID: 19460788
    [Abstract] [Full Text] [Related]

  • 10. Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins.
    Sun BS, Wang JH, Liu LL, Gong SL, Redmond HP.
    J Surg Oncol; 2007 Sep 01; 96(3):241-8. PubMed ID: 17469118
    [Abstract] [Full Text] [Related]

  • 11. The essential role of the mitochondria and reactive oxygen species in Cisplatin-mediated enhancement of fas ligand-induced apoptosis in malignant pleural mesothelioma.
    Stewart JH, Tran TL, Levi N, Tsai WS, Schrump DS, Nguyen DM.
    J Surg Res; 2007 Jul 01; 141(1):120-31. PubMed ID: 17574045
    [Abstract] [Full Text] [Related]

  • 12. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.
    Cole GW, Alleva AM, Reddy RM, Maxhimer JB, Zuo J, Schrump DS, Nguyen DM.
    J Thorac Cardiovasc Surg; 2005 May 01; 129(5):1010-7. PubMed ID: 15867774
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets.
    Barbieri F, Würth R, Favoni RE, Pattarozzi A, Gatti M, Ratto A, Ferrari A, Bajetto A, Florio T.
    Biochem Pharmacol; 2011 Nov 15; 82(10):1467-77. PubMed ID: 21787763
    [Abstract] [Full Text] [Related]

  • 15. p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma.
    Hopkins-Donaldson S, Belyanskaya LL, Simões-Wüst AP, Sigrist B, Kurtz S, Zangemeister-Wittke U, Stahel R.
    Neoplasia; 2006 Jul 15; 8(7):551-9. PubMed ID: 16867217
    [Abstract] [Full Text] [Related]

  • 16. Targeting alpha7-nicotinic receptor for the treatment of pleural mesothelioma.
    Catassi A, Paleari L, Servent D, Sessa F, Dominioni L, Ognio E, Cilli M, Vacca P, Mingari M, Gaudino G, Bertino P, Paolucci M, Calcaterra A, Cesario A, Granone P, Costa R, Ciarlo M, Alama A, Russo P.
    Eur J Cancer; 2008 Oct 15; 44(15):2296-311. PubMed ID: 18722110
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
    Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP.
    J Natl Cancer Inst; 2008 Apr 16; 100(8):580-95. PubMed ID: 18398104
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts.
    Littlejohn JE, Cao X, Miller SD, Ozvaran MK, Jupiter D, Zhang L, Rodarte C, Smythe WR.
    Int J Cancer; 2008 Jul 01; 123(1):202-8. PubMed ID: 18360826
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.